...
首页> 外文期刊>Arthritis Research >Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage
【24h】

Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage

机译:脂质运动型前列腺素D2合酶在骨关节炎软骨中的表达增加

获取原文
           

摘要

Introduction Prostaglandin D synthase (PGDS) is responsible for the biosynthesis of PGD and J series, which have been shown to exhibit anti-inflammatory and anticatabolic effects. Two isoforms have been identified: hematopoietic- and lipocalin-type PGDS (H-PGDS and L-PGDS, respectively). The aims of this study were to investigate the expressions of H-PGDS and L-PGDS in cartilage from healthy donors and from patients with osteoarthritis (OA) and to characterize their regulation by interleukin-1-beta (IL-1β) in cultured OA chondrocytes. Methods The expressions of H-PGDS and L-PGDS mRNA and protein in cartilage were analyzed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry, respectively. Chondrocytes were stimulated with IL-1β, and the expression of L-PGDS was evaluated by real-time RT-PCR and Western blotting. The roles of de novo protein synthesis and of the signalling pathways mitogen-activated protein kinases (MAPKs), nuclear factor-kappa-B (NF-κB), and Notch were evaluated using specific pharmacological inhibitors. Results L-PGDS and H-PGDS mRNAs were present in both healthy and OA cartilage, with higher levels of L-PGDS than H-PGDS (> 20-fold). The levels of L-PGDS mRNA and protein were increased in OA compared with healthy cartilage. Treatment of chondrocytes with IL-1β upregulated L-PGDS mRNA and protein expressions as well as PGD2 production in a dose- and time-dependent manner. The upregulation of L-PGDS by IL-1β was blocked by the translational inhibitor cycloheximide, indicating that this effect is indirect, requiring de novo protein synthesis. Specific inhibitors of the MAPK p38 (SB 203580) and c-jun N-terminal kinase (JNK) (SP600125) and of the NF-κB (SN-50) and Notch (DAPT) signalling pathways suppressed IL-1β-induced upregulation of L-PGDS expression. In contrast, an inhibitor of the extracellular signal-regulated kinase (ERK/MAPK) (PD98059) demonstrated no significant influence. We also found that PGD2 prevented IL-1β-induced upregulation of L-PGDS expression. Conclusions This is the first report demonstrating increased levels of L-PGDS in OA cartilage. IL-1β may be responsible for this upregulation through activation of the JNK and p38 MAPK and NF-κB signalling pathways. These data suggest that L-PGDS might have an important role in the pathophysiology of OA.
机译:简介前列腺素D合酶(PGDS)负责PGD和J系列的生物合成,已显示具有抗炎和抗分解代谢作用。已鉴定出两种同工型:造血型和脂环蛋白型PGDS(分别为H-PGDS和L-PGDS)。这项研究的目的是调查H-PGDS和L-PGDS在健康供体和骨关节炎(OA)患者软骨中的表达,并通过培养的OA表征白介素1-β(IL-1β)对其调节软骨细胞。方法分别采用实时逆转录-聚合酶链反应(RT-PCR)和免疫组织化学方法检测软骨中H-PGDS,L-PGDS mRNA和蛋白的表达。用IL-1β刺激软骨细胞,并通过实时RT-PCR和蛋白质印迹法评估L-PGDS的表达。使用特定的药理抑制剂评估了从头蛋白质合成的作用以及有丝分裂原激活的蛋白激酶(MAPKs),核因子-κB(NF-κB)和Notch信号通路的作用。结果健康和OA软骨中均存在L-PGDS和H-PGDS mRNA,L-PGDS的水平高于H-PGDS(> 20倍)。与健康软骨相比,OA中L-PGDS mRNA和蛋白质的水平增加。 IL-1β处理软骨细胞后,L-PGDS mRNA和蛋白表达以及PGD 2 产生均呈剂量和时间依赖性。 IL-1β对L-PGDS的上调被翻译抑制剂环己酰亚胺阻断,表明该作用是间接的,需要从头合成蛋白质。 MAPK p38(SB 203580)和c-jun N末端激酶(JNK)(SP600125)以及NF-κB(SN-50)和Notch(DAPT)信号通路的特异性抑制剂抑制了IL-1β诱导的IL-1β上调。 L-PGDS表达。相比之下,细胞外信号调节激酶(ERK / MAPK)(PD98059)的抑制剂没有显示出明显的影响。我们还发现PGD 2 防止了IL-1β诱导的L-PGDS表达上调。结论这是第一份证明OA软骨中L-PGDS水平升高的报告。 IL-1β可能通过激活JNK和p38 MAPK和NF-κB信号通路来引起这种上调。这些数据表明,L-PGDS可能在OA的病理生理中具有重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号